Efficacy of intracoronary abciximab in percutaneous coronary interventio

Not Applicable

• Conditions: ST-segment elevation myocardial infarction.; myocardial infarction specified as acute or with a stated duration of 4 weeks (28 days) or less from onset

• Registration Number: IRCT2012081310573N1
• Lead Sponsor: Cardiovascular Research Center, Shahid Beheshti University of Medical sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

ST elevation myocardial infarction (MI)
Exclusion criteria: patients presenting with ST-elevation myocardial infarction after 12 hours from symptoms onset; patients presenting with vasospastic angina (determined by resolution of ST segment elevation, and relief of symptoms after intravenous administration of nitroglycerin); patients presenting with non-ST elevation MI; contraindications for antiplatelets such as bleeding disorder including gastrointestinal bleeding, hematuria, or any known bleeding tendency either inherited or acquired; thrombocytopenia (Platelet count less than 100.000 per microliter; recent (less than 6 months) stroke; intracranial hemorrhage at any time in patient's life or any known intracranial malformation; cardiogenic shock; left bundle branch block changes on ECG.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Infarct size. Timepoint: Day 2. Method of measurement: Area under the curve of the cardiac creatine kinase-MB release.;Myocardial reperfusion. Timepoint: First day. Method of measurement: resolution of ST segment elevation.;Reinfarction. Timepoint: Days 1 to 7. Method of measurement: Recurrent symptoms suggestive of ischemia with new ST-segment elevation and/or elevation of serum cardiac markers levels.